Edition:
United Kingdom

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

18.35USD
22 May 2018
Change (% chg)

$0.09 (+0.49%)
Prev Close
$18.26
Open
$18.32
Day's High
$18.43
Day's Low
$18.32
Volume
11,145
Avg. Vol
332,825
52-wk High
$21.47
52-wk Low
$11.43

Chart for

About

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $2,625.93
Shares Outstanding(Mil.): 143.97
Dividend: --
Yield (%): --

Financials

  HALO.OQ Industry Sector
P/E (TTM): 34.92 237.88 32.90
EPS (TTM): 0.52 -- --
ROI: 31.59 -7.38 12.74
ROE: 82.79 -10.11 14.64

BRIEF-Halozyme Therapeutics Says CEO Helen Torley's 2017 Compensation Was $5.18 Mln ‍​

* HALOZYME THERAPEUTICS INC SAYS CEO HELEN I. TORLEY'S 2017 TOTAL COMPENSATION WAS $5.18 MILLION VERSUS $4.85 MILLION IN 2016 – SEC FILING‍​ Source text - https://bit.ly/2udFEM8 Further company coverage:

22 Mar 2018

BRIEF-Halozyme Reports Q4 Earnings Per Share $0.85

* REITERATED 2018 FINANCIAL GUIDANCE FOR NET REVENUE OF $115 MILLION TO $125 MILLION Source text for Eikon: Further company coverage:

20 Feb 2018

BRIEF-Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018

* HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018

09 Jan 2018

BRIEF-Alexion And Halozyme Enter License Agreement For ENHANZE Technology

* ALEXION AND HALOZYME ENTER LICENSE AGREEMENT FOR ENHANZE TECHNOLOGY Source text for Eikon: Further company coverage:

07 Dec 2017

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.308.75 +1.95
Sanofi SA (SASY.PA) €66.30 +0.12
Eli Lilly And Co (LLY.N) $82.56 +0.73
Albireo Pharma Inc (ALBO.OQ) $32.80 0.00
MannKind Corporation (MNKD.OQ) $1.89 -0.01

Earnings vs. Estimates